Camp4 Therapeutics (CAMP) CFO receives 215,000 stock options grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Camp4 Therapeutics Corp Chief Financial Officer Kelly Gold received a grant of stock options covering 215,000 shares of common stock. The options have an exercise price of $4.46 per share and expire in 2036.

The shares underlying the option vest in equal monthly installments over four years from the grant date, meaning the award functions as long-term, time-based compensation rather than an immediate cash transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gold Kelly

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	215,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 215,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Stock options granted: 215,000 options Exercise price: $4.46 per share Underlying shares: 215,000 shares +3 more

6 metrics

Stock options granted 215,000 options Grant of stock options to CFO Kelly Gold

Exercise price $4.46 per share Exercise price of granted stock options

Underlying shares 215,000 shares Common stock underlying the option award

Total options after grant 215,000 options Total derivative holdings following this transaction

Option expiration date March 31, 2036 Expiration of stock option award

Vesting period 4 years, monthly Equal monthly vesting over four years from grant date

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest in equal monthly installments

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" linked to common stock"

exercise price financial

"conversion_or_exercise_price of 4.4600 per underlying share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date set to 2036-03-31 for the option award"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in equal monthly installments financial

"The shares underlying the option vest in equal monthly installments over a period of four years"

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 04:47 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gold Kelly

(Last)

(First)

(Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$4.46	04/01/2026		A		215,000		⁽¹⁾	03/31/2036	Common Stock	215,000	$0	215,000	D

Explanation of Responses:

1. The shares underlying the option vest in equal monthly installments over a period of four years commencing from the date of grant.

Remarks:

	/s/ Josh Mandel-Brehm, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Camp4 Therapeutics (CAMP) report for its CFO?

Camp4 Therapeutics reported that CFO Kelly Gold received a grant of stock options for 215,000 shares of common stock. The options are a compensation award, not an open-market purchase, and give the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the Camp4 (CAMP) CFO’s new stock options?

The stock options granted to Camp4 CFO Kelly Gold have an exercise price of $4.46 per share. This means she can choose to buy common shares at $4.46, regardless of the market price, once the options have vested and before they expire.

How many Camp4 (CAMP) stock options were granted to CFO Kelly Gold?

CFO Kelly Gold was granted stock options covering 215,000 shares of Camp4 Therapeutics common stock. All 215,000 underlying shares are tied to this single option award, which vests over time and is intended as long-term equity-based compensation.

When do the Camp4 (CAMP) CFO’s stock options vest?

The shares underlying the Camp4 CFO’s stock option vest in equal monthly installments over four years from the grant date. This structure gradually delivers ownership rights over time, encouraging continued service with the company throughout the four-year vesting period.

When do the newly granted Camp4 (CAMP) stock options expire?

The stock options granted to Camp4 CFO Kelly Gold expire on March 31, 2036. She must choose to exercise any vested options before that expiration date; after that, any unexercised options will no longer be valid or exercisable.

Did the Camp4 (CAMP) CFO buy or sell shares in the open market?

The filing shows a grant of stock options, coded as an acquisition award, not an open-market buy or sell. It is a compensation-related derivative grant that provides the right to purchase shares later, rather than an immediate market transaction.